One study did the number crunching here, 9 more weeks of life for the cost. There should be more clinical trial information made public on this one I would hope. BD
The drug, GlaxoSmithKline’s Tyverb (sold in the U.S. as Tykerb), would cost about £20,000 per year (or nearly $40,000); total costs associated with administering the drug are about £80,000 (or nearly $160,000), Dow Jones Newswires notes. One study found that women who received Tyverb survived for 74 weeks, compared with 66 weeks for women who did not receive the drug.
http://blogs.wsj.com/health/2008/07/07/uk-says-glaxos-breast-cancer-drug-isnt-worth-the-money/
0 comments :
Post a Comment